IBI363 in combination with chemotherapy demonstrated encouraging efficacy signals and manageable safety in the first-line treatment of NSCLC with PD-L1 negative or low expression. The 3→1.5 mg/kg dose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results